The initial results suggest that Exact’s test could be an alternative to others on the market, but the findings come from a ...

A planet swings in front of its star, dimming the starlight we see. Events like these, called transits, provide us with ...

As it works to diversify its methods for catching early cases of colorectal cancer, Exact Sciences has put forward clinical ...

Analyst Tycho Peterson of Jefferies assigned a Buy rating on Exact Sciences (EXAS – Research Report), with a price target of $84.00.

Exact’s test could compete with Guardant Health’s Shield blood test, which received approval from the Food and Drug Administration in July.

Analyst Brandon Couillard of Wells Fargo maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price target ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced performance data for its blood-based colorectal cancer (CRC) screening test. Results ...

Positive results of a colon cancer study conducted by Exact Sciences prompt the CEO of competitor Guardant Health to publicly challenge his rival to a bet. Exact’s test could compete with ...

Sep. 19, 2024 — Rising temperatures are thought to reduce the number of ice crystals in clouds, leading to the formation of liquid-dominated clouds. However, a new study has found that Arctic ...

Sep. 13, 2024 — A new study is providing new insights into how next-generation electronics, including memory components in computers, breakdown or degrade over ... Electrically Modulated Light ...

For almost a century, Science News journalists have covered advances in science, medicine and technology for the general public, including the 1925 Scopes “monkey” trial, the advent of the ...